Takahisa Hirose Selected Research

Nateglinide (Starlix)

7/2018	Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study.
9/2015	Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.
7/2014	Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.
4/2006	Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
2/2005	[Effects of nateglinide in impaired glucose tolerance subjects].
1/2005	Hypoglycemia following a nateglinide overdose in a suicide attempt.
12/2002	The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takahisa Hirose Research Topics

Disease

53	Type 2 Diabetes Mellitus (MODY) 06/2022 - 06/2005
20	Insulin Resistance 01/2021 - 12/2004
15	Hypoglycemia (Reactive Hypoglycemia) 10/2021 - 01/2005
14	Hyperglycemia 07/2019 - 06/2005
12	Body Weight (Weight, Body) 11/2020 - 12/2002
8	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 06/2006
8	Atherosclerosis 08/2020 - 10/2006
6	Diabetes Mellitus 10/2021 - 06/2005
4	Weight Gain 05/2021 - 12/2009
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2021 - 01/2016
4	Hypertension (High Blood Pressure) 11/2011 - 04/2007
3	Hypercholesterolemia 05/2013 - 06/2007
3	Glucose Intolerance 12/2005 - 12/2002
2	Diabetic Nephropathies (Diabetic Nephropathy) 03/2022 - 07/2006
2	Body Weight Changes 01/2022 - 08/2017
2	Neoplasms (Cancer) 01/2021 - 01/2010
2	Sleep Wake Disorders 01/2021 - 11/2020
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2021 - 11/2020
2	Obesity 11/2020 - 06/2006
2	Diabetes Complications 10/2018 - 07/2018
2	Cognitive Dysfunction 01/2017 - 01/2014
2	Overweight 01/2009 - 12/2004
1	Kidney Diseases (Kidney Disease) 03/2022
1	Hyperaldosteronism (Conn Syndrome) 03/2022
1	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Drug-Related Side Effects and Adverse Reactions 10/2020
1	Acute Monocytic Leukemia (Acute Monoblastic Leukemia) 08/2020
1	Fetofetal Transfusion (Twin Transfusion Syndrome) 02/2020

Drug/Important Bio-Agent (IBA)

39	Insulin (Novolin)FDA Link 06/2022 - 12/2002
29	Glucose (Dextrose)FDA LinkGeneric 02/2022 - 12/2002
12	Insulin Glargine (Lantus)FDA Link 02/2021 - 02/2006
8	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 04/2007
8	Hypoglycemic Agents (Hypoglycemics)IBA 05/2021 - 02/2006
8	Blood Glucose (Blood Sugar)IBA 07/2019 - 02/2006
8	LipidsIBA 11/2018 - 06/2005
7	Sitagliptin Phosphate (Januvia)FDA Link 01/2021 - 09/2015
7	Nateglinide (Starlix)FDA LinkGeneric 07/2018 - 12/2002
5	Nonesterified Fatty Acids (NEFA)IBA 01/2017 - 06/2005
4	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021 - 01/2017
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2006
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020 - 07/2013
4	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 10/2018
4	Pharmaceutical PreparationsIBA 09/2015 - 04/2006
3	VildagliptinIBA 01/2022 - 07/2014
3	empagliflozinIBA 01/2021 - 01/2019
3	dapagliflozinIBA 01/2020 - 01/2017
3	Triglycerides (Triacylglycerol)IBA 11/2018 - 06/2006
3	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2018 - 09/2008
3	LinagliptinIBA 06/2018 - 11/2016
3	voglibose (Basen)IBA 06/2018 - 04/2006
3	Atorvastatin (Lipitor)FDA Link 05/2013 - 06/2005
3	Antihypertensive Agents (Antihypertensives)IBA 02/2012 - 04/2007
2	AlbuminsIBA 03/2022 - 04/2009
2	Liraglutide FDA Link 10/2021 - 10/2018
2	AcidsIBA 01/2021 - 11/2018
2	SodiumIBA 01/2021 - 01/2019
2	Fatty Acids (Saturated Fatty Acids)IBA 08/2019 - 05/2008
2	Sodium-Glucose Transport ProteinsIBA 12/2018 - 01/2017
2	Therapeutic UsesIBA 12/2018 - 01/2017
2	Pyruvic Acid (Pyruvate)IBA 11/2018 - 08/2008
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 10/2018 - 02/2011
2	Glucagon (Glukagon)FDA Link 01/2017 - 09/2015
2	Rosuvastatin Calcium (Crestor)FDA Link 05/2013 - 01/2009
2	olmesartanIBA 11/2011 - 01/2008
2	Exenatide (Byetta)FDA Link 02/2011 - 12/2009
2	Pioglitazone (Actos)FDA Link 01/2011 - 01/2009
2	LDL CholesterolIBA 05/2010 - 01/2009
2	ApolipoproteinsIBA 03/2009 - 07/2007
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2009 - 06/2007
2	glimepiride (Amarel)FDA LinkGeneric 01/2009 - 12/2004
2	Glycoside Hydrolase InhibitorsIBA 09/2008 - 07/2007
2	Short-Acting InsulinIBA 12/2007 - 02/2006
2	mitiglinideIBA 02/2007 - 02/2006
2	Insulin Aspart (NovoLog)FDA Link 02/2007 - 02/2006
2	SecretagoguesIBA 02/2006 - 12/2002
1	AldosteroneIBA 03/2022
1	ReninIBA 03/2022
1	insulin aspart drug combination insulin degludecIBA 02/2022
1	CanagliflozinIBA 10/2021
1	CarbohydratesIBA 01/2021
1	Uric Acid (Urate)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	GABA-A Receptors (GABA(A) Receptor)IBA 01/2021
1	Ketone BodiesIBA 01/2021
1	HDL CholesterolIBA 01/2021
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2021
1	suvorexantIBA 11/2020
1	Sucrose (Saccharose)IBA 11/2020
1	Growth Hormone (Somatotropin)IBA 08/2020
1	Proteins (Proteins, Gene)FDA Link 08/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2020
1	Amiodarone (Amiodarona)FDA LinkGeneric 02/2020
1	Potassium Iodide (Pima)FDA Link 02/2020

Therapy/Procedure

21	Therapeutics 10/2021 - 12/2005
14	Glycemic Control 07/2018 - 02/2006
3	Activities of Daily Living (ADL) 01/2014 - 01/2010
2	Exercise Therapy (Therapy, Exercise) 06/2018 - 06/2005
1	Injections 06/2022
1	Perinatal Care 02/2020